EUVIMEDEUVIMED entdecken
Crossref

Mechanism of Protein–PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody Formulation

Kohei Soeda, Kengo Arai, Tetsuya Yamamoto, Katsuya Ofuji, Masakazu Fukuda, Daisuke Hashimoto, Yuji Yamanaka

Journal of Pharmaceutical Sciences · 2023-03 · 112 (3) · 653-664

DOI: 10.1016/j.xphs.2022.09.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2023-03. Verfasst von Kohei Soeda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan. Hauptthemen laut MEDLINE: Drug Packaging, Antibodies, Monoclonal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Visible particles (VPs) formation in liquid monoclonal antibody formulations is a critical quality issue. Formulations that include poloxamer 188 (PX188) as a surfactant are prone to the formation of VPs comprising aggregated complexes of protein and polydimethylsiloxane (PDMS; silicone oil) derived from primary containers. However, the mechanisms through which these VPs form are complicated and remain to be fully elucidated. This study demonstrates for the first time the dominant spot and pathway of protein-PDMS VP formation in a particular liquid vial formulation. Specifically, when a vial sealed with a PDMS-coated stopper is stored in an upright position under conditions whereby the antibody solution has become well-adhered to the stopper and an air phase exists in the vicinity, protein-PDMS aggregates form on the stopper and are then desorbed into the drug solution to be detected as VPs. Here, we evaluated the effects of several factors on VP formation: adhesion of the drug solution to the stopper, storage orientation, silicone coating on the stopper, vial material, and hydrophobicity of PX188. Remarkably, we found that changing any one of the factors could significantly affect VP formation. Our findings are instructive for better understanding the mechanisms of VP formation in vial products and can provide strategies for VP mitigation in biotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug PackagingAntibodies, MonoclonalSilicone Oils

Stichwörter der Autor:innen

Antibody drugMonoclonal antibodyProtein aggregationProtein formulationSurfactant

Substanzen

Antibodies, MonoclonalSilicone Oils

Autor:innen und Institutionen

  • Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Analytical Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan. Electronic address: fukuda.masakazu76@chugai-pharm.co.jp.

Zitieren

APA

Soeda, K., Arai, K., Yamamoto, T., Ofuji, K., Fukuda, M., Hashimoto, D., & Yamanaka, Y. (2023). Mechanism of Protein–PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody Formulation. Journal of Pharmaceutical Sciences, 112(3), 653-664. https://doi.org/10.1016/j.xphs.2022.09.027

Vancouver

Soeda K, Arai K, Yamamoto T, Ofuji K, Fukuda M, Hashimoto D, et al. Mechanism of Protein–PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody Formulation. Journal of Pharmaceutical Sciences. 2023;112(3):653-664. doi:10.1016/j.xphs.2022.09.027

BibTeX
@article{Soeda2023,
  author = {Soeda, Kohei and Arai, Kengo and Yamamoto, Tetsuya and Ofuji, Katsuya and Fukuda, Masakazu and Hashimoto, Daisuke and Yamanaka, Yuji},
  title = {Mechanism of Protein–PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody Formulation},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2023},
  volume = {112},
  number = {3},
  pages = {653--664},
  doi = {10.1016/j.xphs.2022.09.027}
}
Kostenlos starten →